Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 78
Healthy volunteers: no

Brief summary:
The purpose of this study is to help answer the following questions:

* To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks.
* To evaluate the safety of LY2599506 in participants with diabetes.
* To determine if LY2599506 has the ability to control blood sugar in participants with diabetes.
* To determine how much LY2599506 should be given to participants.
* To determine if LY2599506 has an effect on a participant's weight.

The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.

Detailed description:

Arms:
arm 1: Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks. arm 2: Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks. arm 3: Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks. arm 4: Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks. arm 5: Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).

Interventions: intervention 1: Placebo intervention 2: LY2599506
Intervention descriptions: intervention 1: Administered po BID, prior to morning and evening meals for 12 weeks. intervention 2: Administered po for 12 weeks

Protocol document: